WEKO3
アイテム
{"_buckets": {"deposit": "6cbc123d-7cfb-474c-b6fb-20803acc3569"}, "_deposit": {"created_by": 1, "id": "65805", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "65805"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00065805", "sets": ["29"]}, "author_link": ["648216", "648218", "648217", "648213", "648215", "648214", "648220", "648219"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2015-11-06", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "【Objective】Astatine 211 (211At, T1/2=7.21h) is one of the attractive alpha emitter as it belongs to the same family as iodine, and the application into radioimmunotherapy (211At-RIT) is expected. We evaluated the biological effects of 211At-RIT both in vitro and in vivo.【Methods】211At was labeled with trastuzumab, anti-HER2 monoclonal antibody, using N-succinimidyl-3-(trimethylstannyl)benzoate. The in vitro cytotoxicity was evaluated by cell growth assay using a human metastatic gastric cancer cell line overexpressing HER2 protein. 211At-labeled trastuzumab, 0.5-2.5 MBq, was injected into mice bearing gastric cancer xenografts to determine the anti-tumor effect in vivo.【Results】211At-labeled trastuzumab showed significant cytotoxicity in vitro and suppressed tumor growth in vivo.【Conclusion】211At-RIT could be an effective treatment to HER2 overexpressing gastric cancer. ", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第55回日本核医学会学術総会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "李, 惠子"}], "nameIdentifiers": [{"nameIdentifier": "648213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川, 純崇"}], "nameIdentifiers": [{"nameIdentifier": "648214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津, 弘太郎"}], "nameIdentifiers": [{"nameIdentifier": "648215", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀, 恒夫"}], "nameIdentifiers": [{"nameIdentifier": "648216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "李 惠子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "648217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川 純崇", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "648218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津 弘太郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "648219", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "648220", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "α線放出核種211Atを用いた放射免疫療法 ", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "α線放出核種211Atを用いた放射免疫療法 "}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/65805", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-11-11"}, "publish_date": "2015-11-11", "publish_status": "0", "recid": "65805", "relation": {}, "relation_version_is_last": true, "title": ["α線放出核種211Atを用いた放射免疫療法 "], "weko_shared_id": -1}
α線放出核種211Atを用いた放射免疫療法
https://repo.qst.go.jp/records/65805
https://repo.qst.go.jp/records/6580528aa3425-268b-4a8e-b207-1c9891fbc127
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-11-11 | |||||
タイトル | ||||||
タイトル | α線放出核種211Atを用いた放射免疫療法 | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× 永津, 弘太郎× 佐賀, 恒夫× 李 惠子× 長谷川 純崇× 永津 弘太郎× 佐賀 恒夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 【Objective】Astatine 211 (211At, T1/2=7.21h) is one of the attractive alpha emitter as it belongs to the same family as iodine, and the application into radioimmunotherapy (211At-RIT) is expected. We evaluated the biological effects of 211At-RIT both in vitro and in vivo.【Methods】211At was labeled with trastuzumab, anti-HER2 monoclonal antibody, using N-succinimidyl-3-(trimethylstannyl)benzoate. The in vitro cytotoxicity was evaluated by cell growth assay using a human metastatic gastric cancer cell line overexpressing HER2 protein. 211At-labeled trastuzumab, 0.5-2.5 MBq, was injected into mice bearing gastric cancer xenografts to determine the anti-tumor effect in vivo.【Results】211At-labeled trastuzumab showed significant cytotoxicity in vitro and suppressed tumor growth in vivo.【Conclusion】211At-RIT could be an effective treatment to HER2 overexpressing gastric cancer. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第55回日本核医学会学術総会 | |||||
発表年月日 | ||||||
日付 | 2015-11-06 | |||||
日付タイプ | Issued |